Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Global Stock · Janus Henderson

Janus Henderson Global Life Sciences Fund Class T (JAGLX)

Ticker JAGLX · · Holdings as of Jun 30, 2026

Expense ratio
0.92%$92/yr per $10k
Net assets
$5.8Ball share classes
Holdings
108

Bottom line

Is JAGLX a good fund? The bottom line

JAGLX is the Class T share class of Janus Henderson Global Life Sciences Fund, an actively managed global stock mutual fund from Janus Henderson.

Its expense ratio is 0.92% — about $92 a year on every $10,000 invested, cheaper than 53% of global stock funds we track.

With $5.8 billion in net assets and 108 holdings, its largest position is Eli Lilly & Co. (9.4%) and the top 10 make up 42.4% of the portfolio.

What stands out

  • No front-end sales load

Updated Nov 19, 2026

What JAGLX invests in

Janus Henderson Global Life Sciences Fund seeks long-term growth of capital.

The Fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that portfolio management believes have a life science orientation. In the Funds pursuit of companies with a life science orientation, the Fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the life sciences sector, which may include companies in the following industry groups: pharmaceuticals; biotechnology; health care services; agriculture; cosmetics/personal care; and medical devices. Generally speaking, the life sciences relate to maintaining or improving quality of life. So, for example, companies with a life science orientation include companies engaged in research, development, production, or distribution of…

From the fund's prospectus (filed Jan 28, 2026).

JAGLX performance

Fund calendar-year total returns, 2016–2025 2016: −12.4%; 2017: +22.5%; 2018: +4.2%; 2019: +29.1%; 2020: +25.4%; 2021: +6.7%; 2022: −2.8%; 2023: +7.4%; 2024: +3.5%; 2025: +24.7% −12% 2016 +22% 2017 +4% 2018 +29% 2019 +25% 2020 +7% 2021 −3% 2022 +7% 2023 +3% 2024 +25% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
JAGLX———
Global Stock median+15.2%+7.6%+9.5%

Source: Fund prospectus, as of

Full JAGLX performance history →

What JAGLX costs

On a $10,000 investment, JAGLX's 0.92% expense ratio costs about $92 a year. The prospectus estimates $1,131 in total costs over 10 years (assuming 5% annual returns). The median global stock fund charges 0.95%.

See the full JAGLX fee table →

JAGLX top 10 holdings

#Holding% of fund
1Eli Lilly & Co.9.41%
2Johnson & Johnson7.09%
3AbbVie, Inc.4.67%
4UnitedHealth Group, Inc.4.54%
5AstraZeneca plc3.93%
6Revolution Medicines, Inc.3.02%
7Argenx SE2.63%
8Novartis AG2.56%
9Thermo Fisher Scientific, Inc.2.33%
10Praxis Precision Medicines, Inc.2.19%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 42.4% of the fund. See all top 25 holdings and asset mix →

Alternatives to JAGLX

More funds like JAGLX →

JAGLX FAQ

What is the expense ratio of JAGLX?
JAGLX's expense ratio is 0.92%, which works out to about $92 a year for every $10,000 invested. The prospectus estimates total costs of $1,131 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is JAGLX a good investment?
It depends on your goals, but the data points to: no front-end sales load. This is general information, not personalized advice.
What does JAGLX hold?
JAGLX's largest holdings are Eli Lilly & Co. (9.4%), Johnson & Johnson (7.1%), AbbVie, Inc. (4.7%), UnitedHealth Group, Inc. (4.5%), AstraZeneca plc (3.9%). It holds 108 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Does JAGLX have a sales load?
No. JAGLX has no front-end sales charge.
Who manages JAGLX?
JAGLX is offered by Janus Henderson through Janus Investment Fund.